You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Anoro Ellipta contains two active substances called umeclidinium and vilanterol. These belong to a group of medicines called bronchodilators.[1]

What is Anoro Ellipta used for?

Anoro Ellipta (umeclidinium/vilanterol) is used to treat chronic obstructive pulmonary disease (COPD) in adults. COPD is a long term condition characterised by breathing difficulties that slowly gets worse.[1]

In COPD the muscles around the airways tighten. This medicine blocks the tightening of these muscles in the lungs, making it easier for air to get in and out of the lungs. When used regularly, it can help to control your breathing difficulties and reduce the effects of COPD on your everyday life.[1]

For further information on Anoro Ellipta (umeclidinium and vilanterol) and potential side effects please see:


  1. Anoro Ellipta 55/22mcg patient information leaflet Last accessed: May 2023

ANORO Ellipta was developed in collaboration with INNOVIVA Inc.


▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting side effects you may get.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the product package leaflet. You can also report side effects directly to HPRA Pharmacovigilance on their website: By reporting side effects, you can help provide more information on the safety of this medicine.

Anoro and Ellipta are registered trademarks of the GlaxoSmithKline group of companies.